C. Benedittis

发表

BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?

M. Baccarani, G. Rosti, G. Martinelli, 2015 .

ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS

G. Martinelli, M. Santucci, S. Soverini, 2016 .

ABL populations by ultra-deep sequencing of the resistant − Unraveling the complexity of tyrosine kinase inhibitor

M. Iacono, A. Kohlmann, T. Haferlach, 2013 .

FOXM 1 TRANSCRIPTION FACTOR : A NEW COMPONENT OF CHRONIC MYELOID LEUKEMIA STEM CELL PROLIFERATION ADVANTAGE † RUNNING HEAD : FOXM 1 in chronic myeloid leukemia

Sara De Santis, G. Rosti, G. Martinelli, 2017 .

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

A. Kohlmann, T. Haferlach, M. Baccarani, 2015, Journal of Cancer Research and Clinical Oncology.

Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications

M. Baccarani, G. Rosti, G. Martinelli, 2012 .

Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage

B. Sangro, R. Golfieri, C. Mosconi, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

M. Iacono, A. Kohlmann, T. Haferlach, 2013, Blood.

Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.

M. Cazzola, R. Fanin, M. Baccarani, 2012 .

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

M. Mancini, G. Specchia, T. Haferlach, 2017, Leukemia.

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

A. Kohlmann, T. Haferlach, T. Lion, 2013 .

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy

M. Baccarani, S. Paolini, G. Rosti, 2013 .

Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)

M. Rondoni, G. Martinelli, G. Stefanini, 2015, Case reports in hematology.